Immunome, Inc.
IMNM
$15.67
-$0.82-4.97%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | -20.14% | 67.84% | 13.37% | -984.00% | -550.03% |
Total Depreciation and Amortization | 6.98% | 176.05% | 131.52% | 243.98% | 328.66% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | -45.22% | -95.70% | -61.00% | 615.55% | 789.35% |
Change in Net Operating Assets | -510.37% | -479.71% | 166.74% | 138.24% | 320.22% |
Cash from Operations | -111.14% | -374.98% | -140.91% | -296.64% | -312.79% |
Capital Expenditure | 61.39% | -69.36% | -293.98% | -132,191.67% | -589.41% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 20.26% | 124.96% | 128.60% | -- | -- |
Cash from Investing | 21.44% | 113.67% | 132.52% | 67,038.89% | -23,925.88% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | -81.51% | -26.06% | 5,421.56% | -- | -- |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | 42.43% | 25.93% | -100.73% | -100.34% | -- |
Cash from Financing | -107.93% | -26.07% | -63.81% | -99.50% | -- |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -8.85% | -33.20% | -251.99% | -118.70% | -1,637.53% |